louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06553300: Auto Transplantation of Wisdom Teeth
Official title: Auto Transplantation of Wisdom Teeth With or Without Platelet Rich Fibrin for Replacement of Non-Restorable Posterior Teeth.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Autotransplantation of Wisdom Teeth
Patelet Rich Fibrin
Lead sponsor: Cleveland Dental Institute
Sponsor class: OTHER
First posted: 2024-08-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Autotransplantation emerges as a viable alternative to tooth extraction and prosthetic restoration when conventional endodontic treatments are unfeasible or contraindicated. The success of autotransplantation is influenced by diverse factors, including root development stage, tooth morphology, surgical technique, extraoral duration, recipient socket shape, recipient bed vascularity, and periodontal ligament cell vitality. Preserving periodontal ligament quality and achieving tissue adaptation are pivotal for successful tooth transplantation. Successful donor tooth replacement is influenced by variables like fitting attempts, alveolus-root distance, extra-alveolar time, surgical skill, and extraction trauma intensity.


Eligibility criteria: Inclusion Criteria:

* male and female
* aged between 20 and 50 years
* devoid of systemic ailments
* complying with the study procedures
* holding an Anesthesiologists classification of 1 or 2
* possessing mandibular or maxillary immature wisdom teeth

Exclusion Criteria:

* systemic diseases that might impede the healing process
* Patients with pacemakers
* Individuals harboring allergies to medications or antibiotics
* active smokers
* patients afflicted with periodontal diseases

Primary outcomes:
measure: Radiographic success
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Dental Institute
state: Ohio
Study officials:
affiliation: Cleveland Dental
name: Waleed Elmallah, DDS
role: STUDY_CHAIR
affiliation: Cleveland Dental
name: Ahmed Hashem, DDS
role: STUDY_DIRECTOR
References:
Clinical trial NCT01017900: Surgery Versus Manual Rupture for Dorsal Carpal Ganglion
Official title: Comparison Between Surgical Excision and Manual Rupture for Dorsal Carpal Ganglion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dorsal Carpal Ganglion
Keywords: surgery
manual rupture
dorsal carpal ganglion
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2009-11-23
Enrollment: 100
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study objectives are to compare the efficacy and safety between surgical excision and manual rupture for dorsal carpal ganglion.The participants with dorsal carpal ganglion will be randomized into 2 groups:surgical excision or manual rupture.The patients will be follow-up for at least 1 yr.Telephone interview will be used for outcome assessment.


Eligibility criteria: Inclusion Criteria:

* patients with dorsal carpal ganglion

Exclusion Criteria:

* underlying rheumatic condition
* bleeding tendency

Primary outcomes:
measure: recurrence rate
timeFrame: 1,2 and 3 years
Secondary outcomes:
measure: time to recurrence
timeFrame: 1,2 and 3 years
measure: DASH score
timeFrame: 1,2 and 3 years
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Songklanakarind hospital
state: Songkhla
Study officials:
affiliation: Department of Orthopaedic Surgery,Faculty of Medicine, Prince of Songkla University, Hat Yai,Songkhla, Thailand 90110
name: Boonsin Tangtrakulwanich, MD.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02009800: ICI-VPH: Impact of HPV Immunisation Schedules Against HPV
Official title: ICI-VPH: Impact Des Calendriers d'Immunisation Contre Les HPV
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Human Papillomavirus Infections
Lead sponsor: CHU de Quebec-Universite Laval
Sponsor class: OTHER
Collaborators: name: Centre hospitalier de l'Université de Montréal (CHUM)
name: Ministere de la Sante et des Services Sociaux
name: Institut National en Santé Publique du Québec
First posted: 2013-12-12
Enrollment: 3364
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This randomised clinical trial aims to determine whether an immunization schedule comprising two doses of Gardasil administered six months apart is non-inferior to a schedule comprising three doses administered at 0, 6 and 60 months for the prevention of HPV-16 and HPV-18 infections that persist for at least six months, up to ten years after the initial vaccination.

The study hypothesis is that the two-dose schedule would offer similar protection as that of a three-dose schedule against persistent HPV-16/18 infections.


Eligibility criteria: Inclusion Criteria:

* Having received two doses of Gardasil in 2008-2009, 2009-2010,2010-2011 or 2011-2012 according to 0, 6 months Schedule (between 4 and 12 months)
* Resident of the regions chosen for the study

Exclusion Criteria:

* Being considered immunosuppressed at time of vaccination (9-10 years-old) or at recruitment visit
* Being pregnant at recruitment visit

Primary outcomes:
measure: Incidence of persistent HPV-16/18 infections
timeFrame: 5 years after recruitment visite
Secondary outcomes:
measure: Geometric mean titres of antibodies and seropositivity for HPV types 6, 11, 16 and 18
timeFrame: 5 years after recruitment visit
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: Centre Hospitalier Uiversitaire de Montréal
state: Quebec
city: Québec
country: Canada
facility: Centre Hospitalier Universitaire de Québec, CHU de Québec
Study officials:
References:
Clinical trial NCT02473900: Evaluating the Bioequivalence of HIP1403, HGP0919
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2015-06-17
Enrollment: 32
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the bioequivalence after administration of HIP1403 and HGP0919 in healthy male volunteers

Detailed description: A randomized, open-label, single dose, crossover clinical trial to investigate and compare the pharmacokinetics between HIP1403 and HGP0919 in healthy male volunteers.

Eligibility criteria: Inclusion Criteria:

1. Healthy male volunteers, age 19 to 45 years.
2. The result of Body Mass Index(BMI) is not less than 18 kg/m2 , no more than 27 kg/m2
3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

1.Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.

Primary outcomes:
measure: Oseltamivir Cmax, AUClast , AUCinf
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48hours (Total 16)
Secondary outcomes:
measure: Oseltamivir Tmax
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir t1/2
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir CL/F
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48hours (Total 16)
measure: Oseltamivir Vd/F
timeFrame: 0h(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48hours (Total 16)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
affiliation: Korea University Anam Hospital
name: Ji Young Park, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00458900: Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
Official title: Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pneumonia
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2007-04-11
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous administrations. As moxifloxacin is known to have a high oral bioavailability in healthy volunteers, patients are switched to oral or enteral therapy as soon as possible. However, no data on plasma levels for moxifloxacin during such a switch-therapy in IC-patients are available. Therefore, this study aims to evaluate the moxifloxacin-plasma levels and their inter-individual variability during IV to enteral switch therapy in IC-patients.


Eligibility criteria: Inclusion Criteria:

* IC patients treated with 400 mg moxifloxacin IV (once a day) that can be switched to enteral administration of 400 mg moxifloxacin.
* IV steady state
* Hemodynamic stability
* Normal enteral feeding without prokinetics
* Presence of arterial line
* Informed consent
* ≥ 18 jaar

Exclusion Criteria:

* Dialysis patients
* Creatinine clearance \< 30 ml/min
* Transaminase levels \> 5x upper limit

Primary outcomes:
measure: Pharmacokinetics
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Kirsten Colpaert, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02757300: Mucosal Injury Using Pharyngeal Packing
Official title: Incidence of Mucosal Injury Using Pharyngeal Packing in Surgery of the Nasal Sinuses
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Sore Throat
Lead sponsor: Marienhospital Osnabrück
Sponsor class: OTHER
First posted: 2016-05-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: After approval of the Institutional Review Board and written patient´s informed consent patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups. After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay.

Detailed description: Aim of the study

Post-operative nausea and vomiting (PONV) is a complication of anaesthesia and responsible for malaise of surgical patients. Furthermore, PONV has been shown causing additive costs due to anti-emetic drugs and prolonged hospitalisation. The occurrence of PONV is multifactorial. Beside individual patients factors, opioid use and type of surgery seem to be responsible for occurrence of PONV. Especially, sinus surgery carries a high risk of PONV. Blood from the operation site entering the stomach has been discussed the potential cause for PONV in this specific patient population.

Therefore, hypopharyngeal packing following orotracheal intubation is a common clinical practice to prevent blood passing through the esophagus and so to lower the incidence of PONV.

Unfortunately, there are limited data data supporting the effectiveness of this procedure. In contrast, some references suggest that hypopharyngeal packing may be associated with postoperative mucosal injury and sore throat with high impact on patients´ well-being.

To evaluate the usefulness and safety of hypopharyngeal packing the investigators perform prospective randomized study with the following objective:

1. Does pharyngeal packing during sinus surgery increase the incidence of mucosal injury?

Eligibility criteria: Inclusion Criteria:

* Surgery of the sinuses
* Patients over 18 years of age
* Duration of surgery \> 1h

Exclusion Criteria:

* Refusal of the patient
* Patients under 18 years of age
* Chemotherapy with antiemetic medication
* Combined surgery (for example tonsillectomie and sinus surgery)
* Pregnancy

Primary outcomes:
measure: Incidence and severity of mucosal injury
timeFrame: Second postoperative day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Marienhospital Osnabrück
name: Martin Beiderlinden, PD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00655200: Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Official title: Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2008-04-09
Enrollment: 2286
Sex: ALL
Minimum age (years): 0
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Type 1 and Type 2 Diabetes

Brief summary: This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus.
* Newly diagnosed insulin naive patients
* Patients currently on human insulin or on basal insulin
* Patients prescribed with Levemir™ FlexPen™ (Insulin Detemir) therapy
* Usage should be in accordance with the current prescribing information (See attached prescribing information)

Exclusion Criteria:

* Previous history of hypersensitivity to Insulin Detemir (Levemir™) and its excipients (See attached prescribing information)
* Contraindications and warnings specified in the current prescribing information (See attached prescribing information)
* Pregnant women, those planning to become pregnant, or women who are breastfeeding
* Patients who are already on human premix or premix analogue (unless they are going to be shifted to basal-bolus therapy)
* Children below 6 years old

Primary outcomes:
measure: Safety profile of Insulin Detemir among Filipino patients
timeFrame: 3 months follow-up visit
Secondary outcomes:
Other outcomes:
Locations:
city: Manilla
country: Philippines
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05837000: Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair
Official title: Role of Adding Dexmedetomidine, Ketamine and Magnesium Sulphate to Caudal Block as Preemptive Analgesia in Hypospadias Repair in Pediatrics: a Randomized Double-blinded Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Preemptive Analgesia
Dexmedetomidine
Ketamine
Magnesium Sulphate
Hypospadias
Pediatrics
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2023-05-01
Enrollment: 75
Sex: MALE
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Caudal epidural block is a rapid, reliable, and safe technique that can be used with general anesthesia for intraoperative and postoperative analgesia in pediatric patients Ketamine is a selective antagonist of N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor.


Eligibility criteria: Inclusion Criteria:

* Aged 1-7 years
* American Society of Anesthesiologists (ASA) classification I and II, undergoing hypospadias repair.

Exclusion Criteria:

* Developmental delay
* Psychological or neurological disorders
* Difficult airway
* Hyperactive airway disease or children in whom caudal block was contraindicated (e.g., infection at the site of block, bleeding disorder, or abnormalities of the sacrum).

Primary outcomes:
measure: First time of rescue analgesia requirement
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Total consumption of rescue analgesia
timeFrame: 24 hours postoperatively
measure: Pain score
timeFrame: 24 hours postoperatively
measure: The incidence of adverse effects
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Karelsheikh University Hospital
state: Karelsheikh
Study officials:
affiliation: Research ethics committee - Kafrelsheikh University
name: Kafrelsheikh University
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01615900: Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
Official title: Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Transplant Patient
Keywords: Renal graft
Teleconsultation
Kidney transplant failure score
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2012-06-11
Enrollment: 155
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The main objective of this study is to optimize the coverage of renal transplant patients thanks to a personalized follow-up based on a risk score of early graft failure (KTFS, Kidney Transplant Failure Score), associated with teleconsultations.


Eligibility criteria: Inclusion Criteria:

* Adult patient
* Having received a deceased donor renal transplant one year ago
* Having an access internet high-speed
* Having a compatible computer and supporting the videoconference
* Calculable KTFS (Kidney Transplant Failure Score)
* Patient having participated in a therapeutic educational program
* Patient has given informed consent
* Patient insured

Exclusion Criteria:

* Patient under age 18
* Patient having received a multi-organ transplant (heart kidney / liver kidney / kidney pancreas / lung kidney / heart lung kidney)
* Patient non-compliant
* BK virus nephropathy or BK positive viremia
* CMV positive viremia
* Identified and treated psychiatric disorders
* Participation in another clinical study
* Pregnancy

Primary outcomes:
measure: Number of serious adverse events
timeFrame: 2 years
Secondary outcomes:
measure: Cost-effectiveness of the personalized follow-up
timeFrame: 2 years
measure: Quality of life linked to the health of transplant patients
timeFrame: 2 years
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
Study officials:
References:
Clinical trial NCT02759900: Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
Official title: Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Actinic Keratosis
Acne/Rosacea
Verruca Plana
Tinea
Molluscum Contagiosum
Bowen's Disease
Warts
Lead sponsor: The Skin Center Dermatology Group
Sponsor class: INDUSTRY
First posted: 2016-05-03
Enrollment: 100
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders

Detailed description: The study uses non-thermal atmospheric pressure plasma to treat target conditions. The patients are monitored at set intervals for efficacy and adverse effects using investigator's assessment and imaging techniques

Eligibility criteria: Inclusion Criteria:

* diagnoses of target conditions
* ability to complete study protocol

Exclusion Criteria:

* based on specific condition

Primary outcomes:
measure: Clinical improvement
timeFrame: 1-12 months
Secondary outcomes:
Other outcomes:
Locations:
city: New City
country: United States
facility: The Skin Center Dermatology Group
state: New York
Study officials:
References:
citation: Malik S, Gill M, Fridman G, Fridman A, Friedman PC. Cold atmospheric plasma reduces demodex count on the face comparably to topical ivermectin, as measured by reflectance confocal microscopy. Exp Dermatol. 2022 Sep;31(9):1352-1354. doi: 10.1111/exd.14584. Epub 2022 May 11. No abstract available.
Clinical trial NCT00172900: MRS and DTI of White Matter in Alzheimer's Disease
Official title: MR Spectroscopy and Diffusion Tensor Imaging of White Matter in Alzheimer's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Alzheimer's Disease
Vascular Dementia
Keywords: Diffusion tensor imaging
MR spectroscopy
dementia
white matter
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 40
Sex: ALL
Minimum age (years): 55
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The white matter change of the Alzheimer's disease could be studied by diffusion tensor image and MR spectroscopy to see the microstructral and biochemical change.


Eligibility criteria: Inclusion Criteria:

* probable Alzheimer's disease or subcortica type vascular dementia

Exclusion Criteria:

* large vessel infarct, major trauma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Medical Imaging, National Taiwan University Hospital
Study officials:
affiliation: Department of Medical Imaging, National Taiwan University Hospital
name: Ya-Fang Chen, MD
role: STUDY_DIRECTOR
References: